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Summary. Understanding how genetic changes allow emerging virus strains to escape the pro-
tection afforded by vaccination is vital for the maintenance of effective vaccines. We use struc-
tural and phylogenetic differences between pairs of virus strains to identify important antigenic
sites on the surface of the influenza A(H1N1) virus through the prediction of haemagglutination
inhibition (HI) titre: pairwise measures of the antigenic similarity of virus strains. We propose
a sparse hierarchical Bayesian model that can deal with the pairwise structure and inherent
experimental variability in the H1N1 data through the introduction of latent variables. The latent
variables represent the underlying HI titre measurement of any given pair of virus strains and
help to account for the fact that, for any HI titre measurement between the same pair of virus
strains, the difference in the viral sequence remains the same.Through accurately representing
the structure of the H1N1 data, the model can select virus sites which are antigenic, while its
latent structure achieves the computational efficiency that is required to deal with large virus
sequence data, as typically available for the influenza virus. In addition to the latent variable
model, we also propose a new method, the block-integrated widely applicable information crite-
rion biWAIC, for selecting between competing models. We show how this enables us to select
the random effects effectively when used with the model proposed and we apply both methods
to an A(H1N1) data set.
Keywords: Antigenic variability; Bayesian hierarchical models; Influenza virus; Latent variable
models; Markov chain Monte Carlo sampling; Mixed effects models; Spike-and-slab prior;
Widely applicable information criterion
1. Introduction
Human inﬂuenza viruses are a major cause of morbidity and mortality world wide, with sea-
sonal epidemics of inﬂuenza estimated to result in 3 million–5 million cases of severe illness
and 250000–500000 deaths (World Health Organization, 2009). Individuals usually mount an
effective antibody-mediated immune response following infection or vaccination that provides
long-lasting protection against a particular strain of the inﬂuenza virus. However, seasonal in-
ﬂuenza viruses evolve rapidly and changes to the parts of the virus (termed antigens) that are
recognized by the immune system enable the virus population to evade existing immunity and
individuals experience recurrent infections. Furthermore the effectiveness of the vaccine, which
remains the most effective means of disease prevention, depends on the constituents being well
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matched to circulating viruses. The continuing antigenic evolution of inﬂuenza viruses requires
a World Health Organization co-ordinated global inﬂuenza surveillance and response system,
which is responsible for the identiﬁcation of new genetic and antigenic variants among circulat-
ing viruses to ensure that inﬂuenza vaccine components reﬂect the antigenic characteristics of
circulating viruses (World Health Organization, 2009).
Inﬂuenza viruses are classiﬁed into three distinct types (A, B andC), of whichA and B viruses
circulate globally in humans and are responsible for seasonal epidemics. Inﬂuenza A viruses are
particularly diverse and are further classiﬁed into subtypes (e.g. A(H1N1)). The inﬂuenza vac-
cine comprises strains of A(H1N1), A(H3N2) and B viruses predicted to elicit the most effective
immune responses against circulating viruses in the forthcoming inﬂuenza season (Barr et al.,
2014). Vaccination provides minimal protection across subtypes and effectiveness within sub-
type is maximized when the vaccine virus is more antigenically similar to circulating viruses.
Genetic mutations cause amino acid substitutions in the surface proteins of the inﬂuenza virus
that affect recognition by the human immune system. The ever-changing antigenic characteris-
tics of inﬂuenza viruses require that the vaccine formulation is reviewed twice annually and is
frequently updated to maintain protection.
The motivation behind this work is to develop models that predict antigenically signiﬁcant
amino acid residues within the inﬂuenza surface proteins. An improved understanding of the
genetic basis of antigenic evolution has the potential to aid the vaccine selection process in a
variety of ways. The development of in silico models which can predict both antigenic residues
and the likely cross-protection that is offered by candidate vaccine viruses strains is vital for
directing these experiments in an efﬁcient manner and reducing the amount of experimental
work that must be carried out. In addition to the identiﬁcation of emerging antigenic variants,
expertsmust anticipatewhich viruses are likely to predominate in forthcoming epidemic seasons.
Models that improve our knowledge of the contributions of changes to amino acid residues to
antigenic evolution have the capacity to enhance the existing evolutionary models that are
currently used to predict which strains will increase or decrease in frequency through time (e.g.
Łuksza and La¨ssig (2014)).
To infer the antigenic importance of genetic changes that have occurred during the evolution
of the virus we require both genetic data and a measure of antigenic similarity. Antigenic prop-
erties of inﬂuenza viruses are largely determined by the surface protein haemagglutinin. Human
antibodies recognize exposed parts of the haemagglutinin, binding and inhibiting it. Amino acid
substitutions (changes) on the surface of the haemagglutinin protein cause loss of recognition
by human antibodies, and the haemagglutination inhibition (HI) assay is commonly used for
antigenic characterization of circulating viruses (Hirst, 1942;WorldHealthOrganization, 2011).
The resulting HI titre, which is used as the response in our model, is used to assess the antigenic
similarity of a circulating test virus to each of a panel of reference strains that typically include
the current vaccine strain and a range of potential future vaccines.
Each HI titre can be associated with genetic data relating to differences between the refer-
ence and test viruses that are used in the assay. The contributions of individual amino acid
substitutions to antigenic evolution can be predicted by comparing amino acid sequences of the
reference and test viruses. In addition to antigenic similarity, HI titres also reﬂect variation in the
binding strength of both antiserum and test virus. Variation in each of these binding strengths
can also be modelled by using evolutionary terms. In our model, these terms are used as the
explanatory variables and the model also takes into account the structure of these variables,
namely that they are the same for any observation that is taken from the same pair of viruses.
Additionally the model also takes into account experimental effects that result from the data
collection process as random effects.
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Various methods have been proposed to account for the experimental variation in the mea-
surements and to select the variables which cause the changes in the measured antigenic vari-
ability. Originally Reeve et al. (2010) used mixed effects models, e.g. Pinheiro and Bates (2000),
to predict the antigenic similarity of foot-and-mouth disease virus (FMDV) strains. Reeve et al.
(2010) ﬁrst selected the random-effect components and then added terms to account for the
evolutionary history of the viruses. Finally a univariate test for signiﬁcance was used on the
residue variables, with a p-value of less than 0.05 corresponding to an antigenically important
residue. A similar method has also been applied by Harvey et al. (2016) to inﬂuenza A(H1N1),
using versions of the data sets that are used here.
Davies et al. (2014) then introduced a sparse hierarchical Bayesian model called
‘SABRE’ for detecting relevant antigenic sites in virus evolution and showed how it out-
performed the method of Reeve et al. (2010). SABRE uses spike-and-slab priors, as pro-
posed in Mitchell and Beauchamp (1988), to improve variables selection and to outperform
the mixed effects least absolute shrinkage and selection operator the lasso (Tibshirani, 1996;
Schelldorfer et al., 2011). In SABRE, the spike-and-slab priors are integrated into a Bayesian
hierarchical mixed effects model, allowing for consistent inference of all parameters and hy-
perparameters, and inference that borrows strength by the systematic sharing and combination
of information; see Gelman et al. (2013). Davies et al. (2017) improved SABRE through the
addition of a biologically signiﬁcant intercept parameter and increased conjugacy between par-
ameters.
The SABRE models of Davies et al. (2014, 2017) do not, however, fully take into account the
structure of the data and are not sufﬁciently computationally efﬁcient to work with the H1N1
data set. The structure of the data comes from the fact that theHI assay is often repeatedmultiple
times for the same reference and test virus pair. Correspondingly, the genetic and evolutionary
data will be the same for any two measurements where the same reference and test viruses are
used. However, as the full set of explanatory variables explicitly depends on which of the two
viruses is used as the reference virus and which was used as the test virus, it is worth noting
that a given pair of viruses will give different explanatory variables if the strains that are used
as reference and test virus are switched. We can use the described structure to improve the
accuracy of SABRE and to increase its computational efﬁciency such that it can now be used
on the H1N1 data set. In the current work we introduce an extended version of SABRE, called
the extended SABRE model eSABRE, through the use of a latent variable model which better
matches the structure of the data. More precisely we introduce latent variables to represent the
underlying HI titre of any given pair of reference and test virus.
In addition to selecting the ﬁxed effects, it is also important to choose the random-effect
components. To do the selection we introduce a variation of the widely applicable informa-
tion criterion, WAIC (Watanabe, 2010): block integrated WAIC, biWAIC, based on integrated
WAIC, iWAIC, as proposed in Li et al. (2016). biWAIC takes into account the speciﬁc structure
of eSABRE and integrates over the latent variables. We describe how this converges to a par-
ticular form of cross-validation (CV) and use a simulation study to quantify the improvement
that it offers over non-integrated WAIC, nWAIC.
In this paper we evaluate the advantages of eSABRE over the previously proposed conjugate
SABRE model. We use simulated data sets that mimic the structure of the H1N1 data set to
show how it offers an improvement in variable selection, as well as an increase in computational
efﬁciency. We also propose and test biWAIC on the simulated data sets to quantify its im-
provement in selecting random-effect components within eSABRE. Finally we apply biWAIC
with eSABRE to the H1N1 data set and identify some known and potential antigenic sites,
comparing the results with those of Harvey et al. (2016).
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2. Data and previous work
The antigenic data that are analysed comprised pairwise measures of antigenic similarity of
viruses of theA(H1N1) subtype obtained by using theHI assay. In these experiments, antiserum
that was created by exposing a ferret to a particular reference virus is measured in terms of its
ability to inhibit the binding of red blood cells (haemagglutination) by a sample of a second
virus: the test virus. The HI assay measures the degree of protection that each reference strain
would provide against the test virus by recording the maximum dilution at which antibodies in
a sample of antiserum from a ferret that was exposed to a particular reference strain remain
able to inhibit a sample of the test virus. A high titre in the test corresponds to a high dilution
of the antiserum and therefore a low concentration of the antiserum being sufﬁcient to cause
inhibition; a low titre conversely corresponds to a low dilution and a high concentration of the
antiserum being required. An antiserum can therefore typically inhibit the virus that is used
to produce the antiserum at high dilutions, but lower dilutions (i.e. higher concentrations and
hence lower titres) are required to inhibit test viruses that are antigenically more dissimilar.
Higher HI titres indicate antigenic similarity, and HI titres typically decrease with increasing
genetic distance between the reference and test viruses.
Previously, Davies et al. (2017) used the conjugate SABRE method with the following prob-
ability distribution to model the HI assay data:
y∼N .y|1w0 +Dwγ +Zb,σ2" I/: .1/
In this probability distribution, y= .y1, : : : , yN/T represents the N log(HI) titre measurements.
The random-effects design matrix Z is set to be the matrix of factor level indicators with N
rows and ‖b‖ columns, where ‘‖ · ‖’ indicates the length of the vector and b is a column vector
of random-effect coefﬁcients. The explanatory variables D are given as a matrix of J columns
and N rows, where J is the number of explanatory variables. The explanatory variables contain
binary indicators of amino acid changes at different residues or information on the phylogenetic
structure. Of the explanatory variables D, only the variables which are inferred to be relevant to
the prediction of y,Dγ , are included in distribution (1) dependent on γ = .γ1, : : : ,γJ /T ∈{0, 1}J .
The relevance of the jth column of D is determined by γj ∈{0, 1}, where feature j is said to be
relevant if γj =1. Similarly wγ is given as the column vector of regressors, where the inclusion
of each parameter is dependent on γ.
However, although the conjugate SABRE method provides a reasonable way of modelling
the HI titre, it does not adequately represent the true complexity of the data. Within the data,
there are multiple measurements y which are taken from the same pair of reference and test
viruses, p, but they are often carried out under different experimental conditions. In the case
of two measurements where the same pair of reference and test virus was used, y1 and y2, the
experimental conditions, Z, for these observations can vary, i.e. Z1 =Z2 or Z1 =Z2. However,
the corresponding explanatory variables D will remain the same, D1 =D2, whenever the same
pair of reference and test viruses is used. It is this structure that motivates the introduction of
the eSABRE method in Section 3.
For each observation yi, the explanatory variables Di include variables that give the differ-
ences in protein structure and evolutionary history between the reference and test viruses. As
an individual strain will always have the same protein structure, for any pair of virus strains
the differences in protein structure remain identical whenever the experiments are carried out,
regardless of which strain is used as the reference strain. More precisely, the explanatory vari-
ables D that give the differences in the protein structure look at whether there is a presence
1 or absence 0 of an amino acid substitution at each speciﬁc residue which is exposed on the
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surface of haemagglutinin protein. Not all of these amino acid substitutions affect antigenicity
but any important changes causing antigenic differences are likely to result in a reduction in the
observed HI titre measurements y.
The viruses that are studied are descended from an evolutionary process and are therefore not
statistically independent entities. Shared evolutionary history means that more closely related
viruses tend to share traits and false support for the role of a substitution in antigenic change
may arise. To account for shared evolutionary history, the evolutionary or phylogenetic tree
representing the relatedness of the viruses studied was incorporated in the analysis by using a
phylogenetic comparative method described by Reeve et al. (2010). Brieﬂy, for any two viruses
in the evolutionary tree, a path can be traced through the tree along the branches that separate
them. For each observation yi, evolutionary variables that are associated with each branch of
the phylogenetic tree indicate whether a branch does (1) or does not (0) form part of the path
separating the reference and test viruses that are used in the HI assay. When we cannot attribute
antigenic differences to amino acid changes directly, it may be possible to attribute the variation
to one of these evolutionary explanatory variables, representing the point in the evolution of
the virus (speciﬁcally a branch of the phylogenetic tree) where the antigenic characteristics of
the virus changed.
In addition to measuring antigenic similarity, HI titres are affected by the binding strength
of both antiserum and test virus. Variation in immunogenicity and avidity result in antisera
and viruses respectively that vary in their baseline titres. To account for evolutionary signal in
this non-antigenic variation, which results in systematically higher or lower titres for related
viruses, further evolutionary variables that are associated with each branch in the phylogenetic
tree indicate whether the branch is present (1) or absent (0) from the evolutionary history of
the test and reference viruses. For any given pair of viruses, these variables explicitly depend on
which of the two was used to create the antiserum and which was used as test virus (see section
6 of the supplementary materials of Davies et al. (2017) for further details).
HI titre measurements usually contain signiﬁcant experimental variation and it is therefore
necessary to include random effects. For the A(H1N1) data set the possible random effects
are laboratory conditions, reference virus and test virus. Laboratory conditions account for
differences in the experimental conditions that are seen on particular days such as the dilution
of reagents. The reference and test virus effects account for antiserum and viruses that tend to
have systematically higher or lower HI titres in all assays in which they are used.
2.1. Influenza A(H1N1)
Inﬂuenza A(H1N1) viruses re-entered the human population in 1977 and cocirculated with
viruses of a second inﬂuenza A subtype, A(H3N2), and inﬂuenza B viruses until their replace-
ment by a novel, distantly related lineage of A(H1N1) viruses in the 2009 swine origin pandemic
(Barr et al., 2014). During the period 1977–2009, the inﬂuenza vaccine included an A(H1N1)
strain which had to be updated on nine occasions to remain antigenically matched to, and there-
fore capable of protecting the human population from, circulating strains. The data set that is
analysed here comprises 43 A(H1N1) viruses collected from 1978 to 2009 that were each used
as both as reference strains contributing antiserum to the HI assay and as test viruses. From
these viruses, 570 different reference and test virus pairs p were tested resulting in 15693 HI
titre measurements y. The mean standard deviation in log(HI) titre values within each pair of
viruses is 0.48 (to two decimal places) and more information about the selection of the virus
pairs can be found in section 2 of the on-line supplementary materials. Once residues with in-
complete genetic data had been removed, there were 279 explanatory variables consisting of 53
surface-exposed residues and 226 variables related to the phylogenetic data.
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Fig. 1. Three-dimensional structure of the influenza A(H1N1) haemagglutinin protein coloured by antigenic
status: haemagglutinin is exposed on the virus surface and is composed of two regions, HA1 and HA2; HA1 is
responsible for binding to host cells and is the primary target for the host immune system;known antigenic sites
and the receptor binding site where changes are also expected to cause variation in the HI assay are shown
in dark grey (proven regions); plausible antigenic regions in the head domain of haemagglutinin are shown
in light grey; implausible antigenic regions in the stalk domain are shown in black, as are surface-exposed
areas of the HA2 part of the protein which was not included in our analysis; this model representation of the
surface of haemagglutinin is based on the resolved structure of influenza A(H1N1) strain A/Puerto Rico/8/34
(Gamblin et al., 2004)
For inﬂuenza viruses, the haemagglutinin surface protein is responsible for binding to host
cells and is also the major target for neutralizing antibodies (Skehel and Wiley, 2000). Con-
sequently changes to the haemagglutinin structure are usually responsible for the requirement
to update vaccine components. The structure of haemagglutinin that is given in Fig. 1 can be
broadly divided into the stalk domain which connects to the virus particle and a head domain
which contains the residues that are involved in binding to the host cell. Experimental studies
have identiﬁed that the major antigenic regions of haemagglutinin are protruding areas in the
head of the haemagglutinin protein surrounding the receptor binding site (Skehel and Wiley,
2000). For A(H1N1), these experiments have identiﬁed four antigenic sites (Caton et al., 1982);
however, other residues are also known to be important (McDonald et al., 2007). We classify
residues as proven if they belong to any of the four antigenic sites or have other experimental
support for their role in antigenicity (e.g. McDonald et al. (2007)), or if they belong to the
receptor binding site where substitutions are expected to inﬂuence HI titres via changes to virus
receptor binding strength. These residues are shown in dark grey inFig. 1.Other haemagglutinin
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residues that are exposed on the surface of the head domain are considered to be plausible anti-
genic residues, whereas residues belonging to the stalk domain are considered unlikely to play
a role in antigenic change and are therefore considered implausible. Plausible and implausible
antigenic candidate residues are shown in light grey and black respectively in Fig. 1.
3. eSABRE
eSABRE is based on the conjugate SABREmodel that was described in Davies et al. (2017) but
with a likelihood that better takes into account the data structure. The change in the structure
is given in Section 3.1 with the remaining sections deﬁning the prior distributions of eSABRE,
keeping to those used for the conjugate SABREmodel as closely as possible. Finally, themodel is
shownasaprobabilistic graphicalmodel inFig. 2 and theparameters are sampled fromtheposte-
rior distribution by usingMarkov chainMonteCarlo (MCMC) sampling described in Section 4.
TheRcode forourmodels is available fromhttps://github.com/vinnydavies/sabre_
methods and
https://rss.onlinelibrary.wiley.com/hub/journal/14679876/series-
c-datasets
and the data can be obtained from http://researchdata.gla.ac.uk/289/ (Harvey
et al., 2016).
3.1. Latent-variable-based likelihood
The probability distribution of the conjugate SABRE method, expression (1), gives a general
model which can be used in a variety of contexts; it does not, however, completely account for
the structure of the data that are used to model antigenic variability and described in Section 2.
Although the experimental conditions, represented by the random effects, usually vary, each
pair of reference and test viruses will have the same explanatory variables. As a result we can
introduce latent variables μy into the model, where each μy,p represents the unknown true value
of the HI titre of any given pair of reference and test viruses, p.
The introduction of the latent variables μy into the model results in the following distribution
for y:
y∼N .y|Mμy +Zb,σ2yI/ .2/
whereM is aN ×P designmatrix where in each row i there is a 1 in the column related to the pair
of reference and test strains fromwhich the observation yi originates, and 0s in the remainder of
the row. This ensures that each yi has the latent variable μy,p which corresponds to its given pair
of reference and test viruses, p. The random effects are added to the likelihood as some of these
factors, e.g. date, affect measurements at the individual level, i.e. they are different for each yi.
We then wish to infer the values of the HI titre measurements of the pairs of virus strains,
μy, based on the differences in the protein structure and evolutionary history of the virus:
μy ∼N .μy|1w0 +Xγwγ ,σ2" I/: .3/
In this distribution,X is a matrix of explanatory variables forμy and has J columns and P rows,
with Xγ then representing the relevant explanatory variables given γ. γ and wγ are deﬁned as
in the ﬁrst paragraph of Section 2. Additionally to this, we also include an intercept parameter
w0, as we expect high underlying HI titre measurements when the two virus strains that are used
are the same, i.e. the explanatory variables are equal to 0. The full model is given graphically in
Fig. 2.
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The structure that is given by the two main probability distributions of eSABRE, given in
distributions (2) and (3), has twomajor advantages over the main probability distribution of the
conjugate SABRE model, given in expression (1). Firstly it allows us to attribute the error to
the correct part of the model better. In the HI titre measurements some of the error comes from
variability within the experiments, e.g. obtaining multiple different results for the same pair of
reference and test viruses under the same experimental conditions, and this is accounted for by
σ2y . Other error will come from the model ﬁt, e.g. our model not truly replicating the underlying
biological process, and this is given by σ2" . Improving the attribution of error means that our
modelmatches betterwith the data collection technique and should lead tomore accurate results
and an improvement in the identiﬁcation of antigenic sites.
The second advantage of eSABRE is signiﬁcantly improved computational efﬁciency. For
example, to run the MCMC simulations to train the model on ‖y‖= 15693 observations, as
discussed in Section 4, it would take SABRE weeks or months to sample the required number
of iterations to achieve convergence and a reasonable sample size after burn-in. In contrast, with
the proposed eSABRE model we can achieve these results in a few days. A detailed comparison
will be provided in Section 6.3, Table 1. The improvement is a result of reducing the computation
that is required to calculate the conditional posterior distribution of γ. In essence, through the
introduction of latent variables eSABRE reduces the posterior distribution ofγ to amultivariate
Gaussian distribution of dimension ‖μy‖ (‖μy‖= 570 in the H1N1 data set), as opposed to
dimension ‖y‖ (‖y‖= 15693) in SABRE. This is important when there is a large number of
variables, P = 279, and we are required to calculate repeatedly the density of a multivariate
Gaussian distribution which scales cubically multiple times for each iteration. This will be
discussed in further detail in Section 4.1.
3.2. Noise and intercept priors
The conditional variance of the residuals, given the latent variables, is deﬁned as σ2y and repre-
sents the variance in the error that is seen in repeated measurements from the HI assay experi-
ments. We give σ2y the conjugate prior
σ2y ∼IG.σ2y |αy,βy/ .4/
where the hyperparameters αy and βy are ﬁxed, as indicated by the grey nodes in Fig. 2.
The variance in distribution (3), σ2" , represents the variance of the discrepancy between the
unknown true HI titre values μy and the HI titre estimates μˆy that are inferred from the ﬁxed
effects. In eSABRE we give it the prior
σ2" ∼IG.σ2" |α",β"/ .5/
where the hyperparameters α" and β" are ﬁxed. σ2" represents the discrepancy between the
unknown true HI titre values for each pair and what is inferred by the ﬁxed effects. σ2" is also
included in the distributions for w0, wγ and μw (deﬁned in Section 3.3), making the model
conjugate rather than semiconjugate, as discussed in chapter 3 of Gelman et al. (2013). The
advantage of this information sharing is that the error variance in terms of model ﬁt is reﬂected
in the distribution of the regression coefﬁcients and this has been further explored in Davies
et al. (2017).
Additionally we also require a prior on our intercept:
w0 ∼N .w0|μw0 ,σ2w0σ2" /: .6/
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We treat the intercept differently from the remaining regressors, wishing to use vague prior
settings so as not to penalize this term and effectively to make the model scale invariant (Hastie
et al., 2009).
3.3. Spike-and-slab priors
Spike-and-slab priors have been used in various contexts and have been shown to outper-
form l1-methods in terms of both variable selection and out-of-sample predictive performance
(Mohamed et al., 2012; Davies et al., 2014, 2017). They were originally proposed by Mitchell
and Beauchamp (1988) as a mixture of a Gaussian distribution and a Dirac delta spike, but
they have also been used as a mixture of two Gaussian distributions (George and McCulloch,
1993, 1997) and as binary mask models, e.g. Jow et al. (2014).
The idea behind the spike-and-slab prior is that the prior reﬂects whether the feature is
relevant on the basis of the values of γ. In this way we expect that wj =0 if γj =0, i.e. the feature
is irrelevant, and conversely it should be non-zero if the variable is relevant, wj =0 if γj =1. A
conjugate Gaussian prior, with σ2" included for further conjugacy, is then assigned where the
feature is relevant and a Dirac delta spike at 0 where it is not:
wj ∼
{
δ0.wj/ if γj =0,
N .wj|μw,σ2wσ2" / if γj =1
.7/
for j ∈1, : : : ,J and where δ0 is the delta function. Here we have a spike at 0 and as σ2wσ2" →∞
the distribution p.wj|γj =1/ approaches a uniform distribution: a slab of constant height. The
prior for the variance of the parameter is then given by
σ2w ∼IG.σ2w|αw,βw/, .8/
where αw and βw are ﬁxed; see Fig. 2.
In addition to σ2w, we use the hyperparameter μw to reﬂect a non-zero prior mean of the
regression coefﬁcients wγ :
μw ∼N .μw|μ0,σ20σ2" / .9/
where the hyperparameters μ0 and σ20 are ﬁxed and σ
2
" is again included in the variance for
further conjugacy. This speciﬁcation comes from our biological understanding of the problem.
In the H1N1 data set we are likely to observe large HI titre values when the reference and
test viruses are the same, represented by the intercept w0. Smaller HI titre values will then be
seen when the reference and test viruses are different, reﬂecting the fact that any amino acid
changes are likely to reduce the similarity between virus strains and meaning that the regression
coefﬁcients wj are likely to be negative.
The ﬁnal part of the spike-and-slab prior is to set a prior for γ, the hyperparameters which
determine the relevance of the variables:
p.γ|π/=
J∏
j=1
Bern.γj|π/ .10/
where π is the probability that the individual variable is relevant. The value of π can either
be set as a ﬁxed hyperparameter as in Sabatti and James (2005), who argued that it should be
determined by underlying knowledge of the problem. Alternatively it can be given a conjugate
beta prior
π∼B.π|απ,βπ/ .11/
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as has been used here. This is a more general model, which subsumes a ﬁxed π as a limiting
case for απβπ={.απ +βπ/2.απ +βπ +1/}→0 and has also been shown to act as a multiplicity
correction in Scott and Berger (2010).
3.4. Random-effects priors
In mixed effects models the random effects bk,g are given group-dependent Gaussian priors.
There are k ∈ {1, : : : ,K} random effects, where we use g as a naming convention to say which
group the random effect belongs to:
bk,g ∼N .bk,g|μb,g,σ2b,g/: .12/
We deﬁne this to have a ﬁxed mean μb,g = 0 and a common variance parameter σ2b,g, with a
conjugate inverse gamma prior for each random-effects group g:
σ2b,g ∼IG.σ2b,g|αb,g,βb,g/ .13/
where αb,g and βb,g are ﬁxed hyperparameters for each g and we deﬁne b∼N .b|0,Σb/ where
Σb = diag.σ2b/ with σ2b = .σ2b,1, : : : ,σ2b,1,σ2b,2, : : : ,σ2b, G/T such that each σ2b,g is repeated with
length ‖bg‖ as shown in Fig. 2. We are aware that the application of conjugate inverse gamma
priors has been disputed by Gelman (2006). However, in our previous work (Davies et al., 2017)
we found no signiﬁcant differences in the results from using the more complex prior that is
recommended in Gelman (2006).
4. Posterior inference
To explore the posterior distribution of the parameters of eSABRE we use an MCMC
algorithm. Having chosen conjugate priors where possible means that we can run a Gibbs
sampler for the majority of parameters (Ripley, 1979; Geman and Geman, 1984), where we
sample the intercept and regression parameters together, and deﬁnewÅγ = .w0,wγ/,XÅγ = .1,Xγ/,
m= .μw0,μw, : : : ,μw/T and ΣwÆγ =diag.σ2wÆ / with σ2wÆ = .σ2w0,σ2w, : : : ,σ2w/T, where each μw and
σ2w is repeatedwith length ‖γ‖=ΣJj=1 γj. These conditional distributions are derived in section 1
of the on-line supplementary materials and given here, where by a slight abuse of notation θ′
denotes all the other parameters, excluding those on the left of the conditioning bar. The only
exception is γ, which is discussed in Section 4.1:
μy|θ′,XÅγ ,Z, y∼N [μy|Vy{MT.y−Zb/=σ2y +XÅγwÅγ=σ2"},Vy], .14/
wÅγ |θ′,XÅγ ,Z, y∼N{wÅγ |VwÆγ .XÅTγ μy +Σ−1wÆγ mγ/,σ
2
"VwÆγ}, .15/
b|θ′,XÅγ ,Z, y∼N{b|.1=σ2y/VbZT.y−Mμy/,Vb}, .16/
μw|θ′,XÅγ ,Z, y∼N{μw|Vμw.1wγ=σ2w +μ0=σ20/,σ2"Vμw}, .17/
σ2y |θ′,XÅγ ,Z,y∼IG{σ2y |‖y‖=2+αy,βy + 12 .y−Mμy −Zb/T.y−Mμy −Zb/}, .18/
σ2w|θ′,XÅγ ,Z, y∼IG{σ2w| ‖wγ‖=2+αw,βw + .1=2σ2" /.wγ − Iμw/T.wγ − Iμw/}, .19/
σ2b,g|θ′,XÅγ ,Z, y∼IG.σ2b,g| ‖bg‖=2+αb,g,βb,g + 12bTg bg/, .20/
σ2" |θ′,XÅγ ,Z, y∼IG{σ2" |.‖μy‖+‖wÅγ‖+1/=2+α",β" + 12Rσ2" }, .21/
π|θ′,XÅγ ,Z, y∼β.π|απ +‖γ‖,βπ +J −‖γ|/, .22/
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wherewe sampleσ2b,g for eachg.WealsodeﬁneVy = {.1=σ2" /I + MTM=σ2y}−1,VwÆγ = .XÅTγ XÅγ +
Σ−1wÆγ /
−1,Vb ={.1=σ2y/ZTZ+Σ−1b }−1,Vμw =.1=σ20 +‖wγ‖=σ2w/−1 andRσ2" =.μy −XÅγwÅγ/T.μy −
XÅγw
Å
γ/+ .wÅγ −mγ/TΣ−1wÆγ .wÅγ −mγ/+ .μw −μ0/T.μw −μ0/=σ20 for notational simplicity.
Collapsing can lead to improved mixing and convergence, e.g. Andrieu and Doucet (1999).
We take advantage of the induced conjugacy to sample the parameters γ, wÅγ , μw, σ
2
" and π as
a series of collapsed distributions rather than through Gibbs sampling:
p.γ,wÅγ ,μw,σ
2
" ,π/=p.γ/p.π|γ/p.σ2" |π,γ/p.μw|σ2" ,π,γ/p.wÅγ |μw,σ2" ,π,γ/ .23/
=p.γ/p.π|γ/p.σ2" |γ/p.μw|σ2" ,γ/p.wÅγ |μw,σ2" ,γ/ .24/
where the conditionality onθ′,X,Zandyhasbeendropped in thenotationand the simpliﬁcation
from equation (23) to equation (24) follows from the conditional independence relationships
that are shown in Fig. 2, exploiting the fact that π is d separated from the remaining parameters
in the argument viaγ. These distributions can be found by collapsing over parameters as derived
in section 1.2 of the on-line supplementary materials.
4.1. Sampling the latent indicators
Sampling γ is computationally expensive, because it does not naturally taking a distribution of
standard form.However, a conditional distribution can still be obtained andDavies et al. (2014,
2017) used collapsing methods following Sabatti and James (2005) to achieve faster mixing and
convergence as follows:
p.γ|θ′,DÅγ ,Z, y/∝
∫
p.γ,π,σ2" ,w
Å
γ ,μw|θ′,DÅγ ,Z,y/dμwdwÅγdπdσ2" .25/
using the likelihood for the conjugate SABREmodel given in expression (1) and the same priors
that are used for eSABRE.The closed form solution of this integral can be found in the appendix
(A.1.5) of Davies (2016).
However, with the likelihood for the conjugate SABRE model given in expression (1) the
computational cost of computing expression (25) becomes dependent on inverting a ‖y‖×‖y‖
matrix. The inversion of this matrix has a computational complexity of O.p2n/ if theWoodbury
identity is used, where p=‖γ‖+ 1 and n=‖y‖. This is a result of integrating over wÅγ to give
a multivariate Gaussian distribution of dimension ‖y‖. For the size of the data sets that were
used in Davies et al. (2014, 2017) this is not problematic: ‖y‖=246 for example. However, with
the H1N1 data set, where ‖y‖= 15693, calculating any distribution with complexity O.p2n/
becomes less practical.
It is at this point that the structure of the two main probability distributions of eSABRE,
expressions (2) and (3), show the huge computational advantage of eSABRE over the conjugate
SABREmodel that was proposed in Davies et al. (2017); see Table 1 in Section 6 for an example
of the improved computational efﬁciency. As in the conjugate SABRE model we use collapsing
methods and collapse over μw, wÅγ , π and σ
2
" . However, whereas the integration over w
Å
γ in the
conjugate SABRE model gives a multivariate Gaussian distribution of size ‖y‖, for eSABRE
we instead obtain a multivariate Gaussian distribution of dimension ‖μy‖ after integrating over
wÅγ :
p.γ|θ′,XÅγ ,μy/∝
∫
p.γ,π,σ2" ,w
Å
γ ,μw|θ′,XÅγ ,μy/dμwdwÅγdπdσ2" .26/
where the full distribution can be found in section 1.1 of the on-line supplementary materials.
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Thisdependenceon‖μy‖ rather than‖y‖ iswhere themain computational cost reductionoccurs,
as in the H1N1 data set ‖μy‖= 570 is much smaller than ‖y‖= 15693. Even with the matrix
inversion having a computational complexity of O.p2n/ rather than O.n3/, this still means that
the computational complexity of evaluating this density in the SABRE method is 27:5 more
than it is in the eSABRE method. It is this reduction in computational costs compared with the
SABRE method that makes eSABRE feasible for the H1N1 data set, where the computational
cost of the SABRE models is prohibitive.
Multiple methods have been proposed for sampling the latent variables γ. Davies et al.
(2014) looked at two of these in particular: the componentwise Gibbs sampling approach and
a Metropolis–Hastings step (Metropolis et al., 1953; Hastings, 1970). In those studies it was
found that block Metropolis–Hastings sampling was the method that offered the quickest con-
vergence of the model based on central processor unit (CPU) time and we have therefore used
this method here.
Block Metropolis–Hastings sampling improves mixing and convergence through proposing
sets S of latent indicator variables γS simultaneously, where γS denotes a column vector of all
the γjs where j∈S and γ−S its complement. The proposals are then accepted with the following
acceptance rate based on the current state c of all the other γs:
α.γÅS ,γ
c
S |θ′,XÅγ ,Z, y,γc−S/ :=min
{
q.γcS |γÅS ,π/p.γS =γÅS ,γc−S |θ′,XÅγ ,Z,y/
q.γÅS |γcS ,π/p.γS =γcS ,γc−S |θ′,XÅγ ,Z,y/
, 1
}
.27/
where q.·/ is a proposal density, which we set to be q.γÅS |γcS ,π/=Πj∈SBern.γÅj |π/. For SABRE
expression (25) is used for computing p.·/ in expression (27), whereas expression (26) is used
for eSABRE. Proposed moves for independent sets of randomly ordered inclusion parameters
γÅS are then accepted if α.γ
Å
S ,γ
c
S |θ′,XÅγ ,Z, y,γc−S/ is greater than a random variable u∼U [0, 1],
until updates have been proposed for all the latent indicator variables. The size of the proposal
sets, S, was investigated in detail in Davies et al. (2014, 2017) and we have followed those
guidelines here when choosing the size of S.
5. Model selection for choosing the random-effect components
There are various methods that can be used to select the random effects that should be used
within a model. Previously Davies et al. (2016) compared tenfold Bayesian CV and WAIC
(Watanabe, 2010), and found that in terms of model selection WAIC achieved a similar per-
formance at a lower computational cost to tenfold Bayesian CV. Here we look at Bayesian
integrated CV (ICV), e.g. Vehtari and Ojanen (2012), and several variations of WAIC that can
be applied to latent variable models.
An alternative approach to those suggested above would be to use spike-and-slab priors to
select the random effects. Although this would require only one model to be ﬁtted, doing so
will come at a large computational cost. This is a result of poor mixing that is associated with
proposing MCMC moves which change entire groups of random-effect coefﬁcients simulta-
neously. Using intramodel approaches for a small number of models in parallel is far more
computationally viable and has therefore been used here.We have further discussed the decision
to choose WAIC-based methods over spike-and-slab prior based methods for the selection of
random-effect components in section 3 of the on-line supplementary materials.
5.1. Integrated cross-validation
Bayesian CV methods are reliable, if computationally expensive, techniques for measuring the
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out-of-sample performance of different models. Bayesian ICV, e.g. Vehtari and Ojanen (2012),
is a special version of CV which works well in latent variable models. Bayesian ICV integrates
over the latent variables, in this case μy, to give the following utility function for k-fold Bayesian
ICV:
pICV = 1
K
K∑
k=1
log
(
1
I
)
I∑
ι=1
N.yk|MkXÅγ,kwÅ,ιγ +Zkbι,σι,2y Ik +σι,2" MkMTk / .28/
where the yk, XÅγ,k and Zk are the held-out data for validation and there are I iterations of
the MCMC scheme. The distribution comes from integrating over μy in the distribution given
by the product of distributions (2) and (3). The parameter samples, wÅ,ιγ , b
ι, σι,2y and σ
ι,2
" for
ι∈{1, : : : , I}, are taken by using theMCMCalgorithm to sample from the posterior of eSABRE
applied to y−k, X−k, Z−k and M−k.
5.2. Block integrated WAIC
WAIC, as proposed in Watanabe (2010), is natural for selecting the correct model when the un-
derlying model is singular, i.e. models with a non-identiﬁable parameterization, such as SABRE
and eSABRE.WAIChas been proven to be asymptotically equivalent to Bayesian leave-one-out
CV (LOOCV) in Watanabe (2010) and is computed as follows from posterior samples of the
model parameters θι for ι∈{1, : : : , I}:
pWAIC =−2
N∑
i=1
(
log
{
1
I
I∑
ι=1
p.yi|θι,Xγ,i,Zi/
}
−var[log{p.yi|θι,Xγ,i,Zi/}]
)
, .29/
where var is the sample variance with respect to θι, andXi andZi are the ith row of the ﬁxed and
random-effects design matrices respectively. WAIC can be used for a wide variety of problems;
however, it is only justiﬁable for problemswhere the observed data are independently distributed
with a population distribution, e.g. SABRE where the joint likelihood is given by expression
(1). The inclusion of latent variables in eSABREmeans that the observed data are not modelled
with independent distributions and it is therefore inaccurate to use WAIC with eSABRE.
To make WAIC more applicable to latent variable models such as eSABRE, Li et al. (2016)
introduced two alternative versions of WAIC: non-integrated WAIC, nWAIC, and integrated
WAIC, iWAIC. nWAIC applies WAIC to the predictive density of the observed variables y=
.y1, : : : ,yN/, conditionally on the model parameters θ and the potentially correlated latent
variables ψ= .ψ1, : : : ,ψN/:
pnWAIC =−2
N∑
i=1
(
log
{
1
I
I∑
ι=1
p.yi|θι,ψιi ,Zi/
}
−var[log{p.yi|θι,ψιi ,Zi/}]
)
.30/
where θι and ψιi are sampled from the posterior distribution via MCMC sampling and var is
the sample variance. In the proposed eSABRE, taking just the likelihood for yi from distribu-
tion (2) would be the distribution corresponding to p.yi|θι,ψιi ,Zi/ and would not satisfy the
independence assumptions ofWAIC-based methods as each yi is dependent on a latent variable
ψi which is shared by other observations.
Only using the likelihood of the model, e.g. distribution (2), in equation (30) also means that
nWAIC does not account for the mismatch in the model ﬁt of the latent variables as they are
described in distribution (3). This means that nWAIC does not take into account how well the
latent variables are predicted by the explanatory variables. Li et al. (2016) therefore proposed
iWAIC:
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piWAIC =−2
N∑
i=1
(
log
{
1
I
I∑
ι=1
p.yi|θι,Xγ,i,Zi,ψι−i/
}
−var[log{p.yi|θι,Xγ,i,Zi,ψι−i/}]
)
.31/
where var is the sample variance and the distribution that is used is given byp.yi|θι,Xγ,i,Z,ψι−i/
=∫ p.yi|θι,ψι−i,ψi,Z/p.ψi|θι,Xγ/dψi, the analytical integrationof the latent variables from the
product of the likelihood and the distribution of the latent variables.
The proposed version of iWAIC does not, however, work with eSABRE. This is because
each observation yi does not have its own corresponding latent variable ψi. Instead any two
observations y1 and y2 from the same pair of reference and test viruses, p, will have the same
latent variable, i.e.ψ1=ψ2 =μy,p. Under thismodel, i.e. where ρ.ψ1,ψ2/=1, it ismathematically
intractable to integrate over ψ1 =μy,p without integrating over ψ2 =μy,p, something which is
required to calculate p.yi|θι,Xγ,i,Zi,ψ−i/ as needed for equation (31).Wemust therefore either
use nWAIC given by equation (30) or ﬁnd an alternative.
In this current work we propose biWAIC, which is a new modiﬁcation of WAIC for latent
variablemodels with latent variables that are either completely correlated or have no correlation.
In the eSABRE method we use the latent variables μy, where it is possible for two observations
that have the same latent variables, e.g. ψ1 =ψ2 =μy,p, in replacement of ψ. Unlike WAIC,
nWAIC and iWAIC, which rely on using independent distributions for each yi, biWAIC instead
uses a distribution for independent groups of observations yp with the same associated latent
variable. In thisway, yp is the group containing all yi whose virus pairpi is the same as the group’s
virus pair p. Given this speciﬁcation of groups, it is then possible to integrate analytically over
the corresponding latent variable μy,p of the product of the likelihood and the distribution of
the latent variables taken from distributions (2) and (3): p.yp|θι,Xγ,p,Z/=
∫
p.yp|θι,μy,p,Z/
p.μy,p|θι,Xγ,p/dμy,p. biWAIC can then be written as
pbiWAIC =−2
P∑
p=1
(
log
{
1
I
I∑
ι=1
p.yp|θι,Xγ,p,Zp/
}
−var[log{p.yp|θι,Xγ,p,Zp/}]
)
.32/
where var is the sample variance.
Aswell as being applicable to eSABREand particular speciﬁcations of latent variablemodels,
biWAIC can also be shown to have some useful asymptotic properties. Previously Watanabe
(2010) has shown that WAIC is asymptotically equivalent to Bayesian LOOCV, based on the
fact that Bayesian LOOCV loss is asymptotically equivalent to WAIC as a random variable.
Although biWAIC is not asymptotically equivalent to Bayesian LOOCV, on the basis of the
same proof of Watanabe (2010) we can determine that it is asymptotically equivalent to a
different form of Bayesian CV. From looking at equations (28) and (32), along with the two
distributions from which those equations are derived (distributions (2) and (3)), we can see
that, if ICV is evaluated on the same groups as biWAIC, then it is asymptotically equivalent
to biWAIC as a random variable. biWAIC is therefore asymptotically equivalent to Bayesian
leave one group out CV, where observations are divided into P independent groups based on
the number of different virus pairs (groups), as opposed to n groups of single observations for
Bayesian LOOCV.
5.3. Summarizing remarks
In summary, we have discussed ICV, e.g. Vehtari and Ojanen (2012), which is a version of CV
that is designed for latent variablemethods but is computationally expensive. A computationally
cheaper alternative is WAIC and this has been shown to give similar performance in some cases
(Davies et al., 2016).However, standardWAIC is not appropriate for latent variablemodels such
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as the eSABRE method as it assumes independence between observations. nWAIC, proposed
in Li et al. (2016), naively applies WAIC to the likelihood of the model, distribution (2), but
does not take into account the ﬁt of the latent variables, distribution (3). As an improvement,
Li et al. (2016) also proposed iWAIC for latent variable models, but this is not suitable for the
eSABRE method as each observation yi does not have an individual latent variable ψi. Instead
we propose biWAIC which allows for the latent variable structure of the eSABRE method and
takes into account both distribution (2) and distribution (3) by effectively applying iWAIC at a
group level rather than an individual level.
6. Simulation studies
6.1. Simulated data sets
In this section we describe the simulated data sets that are used to test the effectiveness of
eSABRE proposed here and compare it with the conjugate SABRE model that was described
in Davies et al. (2016).
6.1.1. Inﬂuenza-inspired simulated data
To test initially eSABRE and the conjugate SABRE model we generated three data sets with a
reasonably small number of variables. These three data sets are based on the same structure as
the inﬂuenza data sets with a varied number of random-effect factors. In each of the data sets
2000 observations were simulated from 55 pairs of viruses. The 55 pairs of viruses come from
having 10 viruses tested against each other (. 102 /=45) plus the viruses tested against themselves
(expression (10)), with each of these pairs then given 50 possible ﬁxed effects and four possible
random-effect components (including the reference and test viruses). The random-effects groups
were included with probability 0.5 and given zero coefﬁcients otherwise, whereas the relevant
coefﬁcientswere generated fromazero-meanGaussiandistributionwith each componenthaving
a ﬁxed variance drawn from U.0:2, 0:5/. Fixed effects wj were given non-zero values generated
from a uniform distribution, U.−0:4, −0:2/, with inclusion probability π∼U.0:2, 0:4/. σ2y and
σ2" were both set to be 0.033, 0.1 and 0.3 for the three simulated data sets.
6.1.2. Foot-and-mouth disease virus simulated data
To make the simulation studies more realistic we wanted to make simulated data sets based on
the inﬂuenza A(H1N1) data set that was described in Section 2.1. However, although this does
not cause any problems for the proposed eSABRE model, using the conjugate SABRE model
to analyse data sets of this size is computationally prohibitive. Therefore instead we have created
20 simulated data sets based on the extended South African Territories type 1 FMDV data set
that was used in Reeve et al. (2016) and Davies et al. (2017). These data sets were created to be
the same size as the FMDV data sets by using the maximum a posteriori parameter estimates of
the eSABREmethod applied to the South African Territories type 1 FMDV data set. However,
to highlight the differences in performance of the two models under different circumstances,
we varied the error of the underlying model, σ2" ∈ {0:02, 0:2, 0:5}, and changed the mean of
the regression parameters, μw ∈ {−0:1, −0:3, −0:5}. Following Reeve et al. (2016) we used
three random-effect components: the test virus, the date of the experiment and the antiserum
(reference virus).
6.1.3. Simulated data for model selection
Finally, to compare nWAIC, biWAIC and tenfold Bayesian ICV, we have generated nine sets
of 20 data sets with up to four random effects: the test virus, the reference virus and two generic
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random-effect factors. The data sets were generated with 50 possible ﬁxed effects and up to four
random-effect factors included with probability 0.5. Of the nine sets of data sets, three contain
10 virus strains, where each virus strain has been used as both a reference and a test virus,
meaning that there are 55 pairs of reference and test viruses; see Section 6.1.1. Following the
same set-up, three of the sets of data sets include 30 virus strains (465 pairs) and the other three
have 45 virus strains (1035 pairs). Within each of these sets of three data sets, the model error
σ2" was varied to be either 0.1, 0.3 or 0.5.
6.2. Computational inference
For the simulated data we generated 10000 parameter samples from the model, removing 2000
for burn-in. We have previously explored speed of parameter convergence extensively in Davies
et al. (2014, 2017). In that work we established the amount of samples required to achieve
convergencebasedonusing four chains andpotential scale reduction factorsPSRF(Gelmanand
Rubin, 1992). For this we took the threshold of convergence to be PSRF1:1 and terminated
the burn-in phase when this was satisﬁed for 95% of the variables. Given that the trace plots
and other diagnostic plots indicate that the model parameter proﬁles give similar parameter
sample trajectories characteristics to those tested in Davies et al. (2014, 2017), we have used the
MCMC speciﬁcation as established in Davies et al. (2014, 2017) to reduce the computational
requirements of the multiple simulation studies that we have implemented. An example of the
computational requirements to do this is provided in Table 1, part (b).
For the H1N1 data set we generated four chains of parameter samples and computed the
PSRFs. We took the threshold of convergence to be PSRF 1:1 and terminated the burn-in
phase when this was satisﬁed for 95% of the variables.
The ﬁxed hyperparameters, which are shown as grey nodes in Fig. 2, were set the same
for both the eSABRE and conjugate SABRE methods such that αb =βb = .0:001, : : : , 0:001/,
αw =βw =αy =βy =α" =β" =0:001, μ0 =0, σ20 =100, w0 =max.y/, απ =1 and βπ =4 following
Davies et al. (2017).
6.3. Results for the simulation studies
Table 1, part (a), gives the area under the receiver operating characteristic curve values AUC for
eSABRE proposed here and the conjugate SABRE model that was described in Davies et al.
(2017) applied to the inﬂuenza-inspired simulated data sets from Section 6.1.1. The AUC-values
are calculated on the basis of the correct selection or exclusion of the various ﬁxed effects in
the model, where variables are ranked on the basis of the proportion of times that they are
selected in the model. For each combination of data set and number of observations, eSABRE
offers a clear improvement in terms of global variable-selection performance over SABRE.
This improvement is a result of the latent variable structure of eSABRE which better reﬂects
the data generation process, where the difference in the models can be seen by comparing the
probabilistic graphical models in Fig. 2 here and Fig. 1 in Davies et al. (2017). Table 1, part (a),
shows how this improvement is more signiﬁcant as the effect of the latent variable structure is
increased, i.e. as σ2" is increased. As the error variances grow larger, e.g. 0.1 and 0.3, eSABRE
offers a much clearer improvement over the conjugate SABRE model than it did it in the data
set where the error variances are smaller: 0.033. This is because the conjugate SABRE model
and eSABREbecomemore similar as σ2" →0.Given the large variance inHI titremeasurements
(0.23 (to two decimal places) for the H1N1 data), for any given pair of reference and test viruses
in the H1N1 data set, this improvement is vital. Additionally we have shown that the eSABRE
method outperforms the conjugate SABRE method in terms of out-of-sample prediction: see
Table 1 in the on-line supplementary materials.
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Table 1. AUC-values and CPU times for eSABRE and the conjugate SABRE model applied to the
influenza-inspired simulated data sets†
Observations Results for eSABRE Results for conjugate SABRE
σ2y ,σ
2
" =0.033 σ2y ,σ2" =0.1 σ2y ,σ2" =0.3 σ2y ,σ2" =0.033 σ2y ,σ2" =0.1 σ2y ,σ2" =0.3
(a) AUC-values
500 0.98 0.90 0.82 0.90 0.77 0.64
1000 0.98 0.91 0.82 0.83 0.70 0.59
2000 0.98 0.92 0.83 0.75 0.61 0.58
(b) CPU times (s) per 1000 iterations
500 25 25 47 497 867 444
1000 29 26 36 6931 5623 5546
2000 32 25 43 35231 32243 20904
†The table gives the AUC-values and the CPU times per 1000 iterations for eSABRE and the conjugate
SABRE model. The results come from when the methods were applied to the inﬂuenza-inspired simulated
data sets described in Section 6.1.1. with varied numbers of observations.
‡The simulationswere runona clusterwithover 30machines, themajority ofwhichhaddifferent speciﬁcations.
Generally themajority of thesemachines range from12 to 40 cores and 8–32Gbytes of random-accessmemory
and have a variety of processors.
Another notable result from Table 1, part (a), is the reduction in performance in terms of
AUC-values of the conjugate SABRE model as the number of observations increases. This is
an unexpected result as we would expect more data to provide more information to the model,
resulting in a better selection of variables in the models and higher AUC-values. The reason for
this unexpected result is a consequence of the mismatch between the data generation process
where variance in the observations comes in two forms, σ2" and σ
2
y , and the model which only
directly accounts for the variance in y given by σ2y .
Todemonstrate that the unexpected reduction in performance of the conjugate SABREmodel
is a result of the mismatch between the data and the model we completed a small simulation
study with linear models. We generated groups of data sets with 500, 1000 and 2000 observa-
tions generated from a linear model with each group containing 2000 data sets. For each of
these groups, half the data sets have observations generated with independent and identically
distributed noise, e.g. y∼N .y|Xw,σ2yI/. The other half of the data sets were given correlated
errors based on integrating over a set of random effects, e.g. y∼N .y|Xw,σ2yI+σ2"MMT/. This
is equivalent to integrating over the latent variables but allows us to use the same X and w for
a fair comparison. Additionally each of the data sets contains two variables, one relevant, xr,
and one irrelevant, xir. We then calculated the marginal likelihood for each of the four possible
models
(a) no variables included, p.y|·/,
(b) irrelevant variable included only, p.y|xir/,
(c) relevant variable included only, p.y|xr/, and
(d) both variables included, p.y|xir,xr/,
under the assumption of IID noise, as the conjugate SABRE model assumes (incorrectly) with
the H1N1 data, where we have ﬁxed σ2w and marginalized out σ
2
y and w. We can then use these
marginal likelihoods to calculate the probability that the irrelevant variable is included in the
ﬁnal model M via Bayes theorem as follows:
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Fig. 3. Boxplots showing the effect of non-IID Gaussian noise on a model assuming IID Gaussian noise
(the boxplots show the probability that an irrelevant variable is included in a model for data with IID Gaussian
noise ( ) against the probabilities for a model with a noise structure based on the H1N1 data set ( ); the
results show the probability that the irrelevant variable is included in the model decreases as the number of
observations increases for the data with IID Gaussian noise; conversely it shows an increase in the probability
of its inclusion as the number of observations increases when there is a noise structure based on the H1N1
data set): (a) 500 observations; (b) 1000 observations; (c) 2000 observations
P.xir ∈M/=
p.y|xir/+p.y|xir,xr/
p.y|·/+p.y|xir/+p.y|xr/+p.y|xir,xr/
: .33/
Fig. 3 gives boxplots of the probability that the irrelevant variable xir is included in the ﬁnal
model for each of the data sets from our small simulation study. The boxplots show the effect
on the probabilities caused by the different types of noise and varied amounts of observations.
Fig. 3 shows that, as the number of observations increases, the chance that the irrelevant variable
will be included decreases for the IID noise, as would be expected. However, for the non-IID
noise based on the FMDVand inﬂuenza data sets, the results show an increase in the probability
that the irrelevant variable will be included as the number of observations increases, indicating
that the model mismatch that is inherent in SABRE is what causes the unexpected results in
Table 1, part (a).
Table 1, part (b), shows the improvement that eSABRE offers over the conjugate SABRE
model in terms of computational efﬁciency. Table 1, part (b), shows how the conjugate SABRE
model becomes far more computationally expensive as the number of observations increases,
whereas the required CPU time hardly changes for eSABRE if the number of pairs of reference
and test viruses remains the same. This improvement in terms of computational efﬁciency ex-
plains why it is viable to use eSABRE on the H1N1 data set for example, where ‖y‖= 15693
and P =570, but not the conjugate SABRE model that was described in Davies et al. (2017).
Table 2 shows the effectiveness of eSABRE on larger more realistic data sets (Section 6.1.2)
based on the real life FMDV data from Reeve et al. (2016). Like Table 1 the results of Table 2
again show that eSABRE clearly outperforms the conjugate SABRE model in all scenarios
from Section 6.1.2, except for the data set where μw =−0:1 and σ2" . The results show that, as the
model error in the simulated data increases, the conjugate SABRE model seriously drops off in
performance whereas eSABRE remains reasonably consistent. Like with the results of Table 1,
the difference in performance is again caused by the mismatch between the conjugate SABRE
model and the underlying data generation process. As σ2" increases, the SABREmethodmatches
the data generation process less, whereas eSABRE can model this change in value.
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Table 2. Table of AUC-values for eSABRE and the conjugate SABRE model
when applied to the FMDV-based simulated data sets†
μw Results for eSABRE Results for conjugate SABRE
σ2" =0.02 σ2" =0.2 σ2" =0.5 σ2" =0.02 σ2" =0.2 σ2" =0.5
−0:1 0.67 0.67 0.63 0.69 0.60 0.57
−0:3 0.72 0.70 0.67 0.71 0.61 0.58
−0:5 0.75 0.74 0.73 0.72 0.64 0.57
†The table gives AUC-values for eSABRE and the conjugate SABRE model,
when applied to the FMDV-based simulated data sets described in Section 6.1.2.
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Fig. 4. Bar plot of F1-scores given in Table 3: the bar plot compares the F1-scores for nWAIC ( ), biWAIC
( ) and Bayesian tenfold ICV ( ) in terms of correctly selecting random-effect components for the data set
described in Section 6.1.3; the figure takes the results from Table 3
To compare the methods that were described in Section 5, nWAIC, biWAIC and Bayesian
tenfold ICV, we have looked at their performance in terms of correctly selecting random-effect
factors on the data sets from Section 6.1.3. The results are given in Table 3 and are displayed
visually in Figs 4 and 5.
The results in Table 3 show that all of the methods, nWAIC, biWAIC and Bayesian tenfold
ICV, perform similarly in terms of their overall accuracy in correctly including or excluding
random-effects factors. The similarity is best demonstrated by looking at the F1-scores, which
consider both precision and recall, offering a more general assessment of performance than
looking at them separately. (F1-score= 2.precision× recall/=.precision+ recall/, sensitivity=
recall=TP/(TP+FN), speciﬁcity=TN/(TN + FP) and precision=TP/(TP + FP), where we de-
ﬁne the following parameters: true positive TP, false positive FP, true negative TN and false
negative FN.) The F1-scores from Table 3 can also be seen in Fig. 4 where the results are shown
as bar plots. With the results from Table 3 and Fig. 4 suggesting that the information criteria
nWAIC and biWAIC give similar selection performances to Bayesian tenfold ICV, it is reason-
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Table 3. Table of results looking at the random-effects factor
selection performance of the methods described in Section 5†
P σ2" nWAIC biWAIC Bayesian
tenfold ICV
Sensitivity 55 0.1 0.90 0.97 0.92
55 0.3 0.92 0.90 0.89
55 0.5 0.78 0.71 0.93
465 0.1 0.97 0.94 0.85
465 0.3 0.86 0.84 0.86
465 0.5 0.95 0.90 0.86
1035 0.1 0.93 0.71 0.98
1035 0.3 0.91 0.79 0.87
1035 0.5 0.90 0.66 0.74
Speciﬁcity 55 0.1 0.68 0.56 0.15
55 0.3 0.70 0.60 0.41
55 0.5 0.59 0.54 0.26
465 0.1 0.45 0.60 0.66
465 0.3 0.49 0.63 0.63
465 0.5 0.37 0.56 0.53
1035 0.1 0.32 0.60 0.47
1035 0.3 0.33 0.52 0.33
1035 0.5 0.39 0.55 0.29
F1-score 55 0.1 0.80 0.80 0.65
55 0.3 0.88 0.84 0.79
55 0.5 0.72 0.66 0.70
465 0.1 0.70 0.75 0.73
465 0.3 0.70 0.74 0.75
465 0.5 0.73 0.76 0.72
1035 0.1 0.73 0.69 0.80
1035 0.3 0.77 0.74 0.75
1035 0.5 0.60 0.54 0.60
†The table gives results in terms of the successful selection or exclu-
sion of random-effects factors when using themethods described in
Section 5, nWAIC, biWAIC and Bayesian tenfold ICV, on param-
eter samples from the posterior distribution of eSABRE applied to
the simulated data from Section 6.1.3, where P is the number of
pairs of reference and test strains. The results are given as sensitiv-
ities, speciﬁcities and F1-scores, which are calculated based on the
correct inclusion or exclusion of random-effects factors. The results
are displayed in an alternative manner in Figs 4 and 5. F1-scores,
sensitivity and speciﬁcity are deﬁned in the text.
able to use one of the former criteria on the inﬂuenza data set in Section 7, where Bayesian
tenfold ICV will be computationally onerous. Additionally we ﬁnd that there is no difference
in terms of out-of-sample performance between the models that are selected by nWAIC and
biWAIC: see Table 2a in the on-line supplementary materials.
Although suggesting that themethods perform similarly overall in terms of F1-scores, Table 3
also indicates that the methods operate with different sensitivity versus speciﬁcity trade-offs,
meaning that on average some methods include more random-effect factors than others. This
can be seen by looking at the sensitivities and speciﬁcities of nWAIC, biWAIC and Bayesian
tenfold ICV in Table 3 or alternatively by looking at Fig. 5. Fig. 5 plots the sensitivities that are
achieved by the various methods on each set of data sets against the complementary speciﬁcity
(i.e. 1 minus speciﬁcity) and shows that the biWAIC-method operates at a higher threshold for
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Fig. 5. Plot of sensitivities and 1 minus specificities for the results given in Table 3: the plot compares nWAIC
(), biWAIC () and Bayesian tenfold iCV (4) in terms of correctly selecting random-effect components for the
data set described in Section 6.1.3; the figure takes the results from Table 3 and plots the sensitivities against
the complementary specificities (i.e. 1 minus specificities), i.e. as single points from a receiver operating
characteristic curve
inclusion, meaning that it selects less random-effect factors in the model on average. This can
be seen by noting the lower sensitivities and higher speciﬁcities in Fig. 5 or Table 3.
The reason for the difference between nWAIC and biWAIC in terms of the average num-
ber of random-effect factors that are included is a result of the distribution from which they
measure the sample means and variances that are needed to calculate the criterion. nWAIC,
equation (30), takes its sample means and variances on the basis of only the distribution of y,
distribution (2), the distribution which contains the random-effects speciﬁcation. biWAIC, ex-
pression (32), however, takes its sample means and variances from themarginalized distribution
of y whereμy has been integrated out as detailed in Section 5.2. As a result, like Bayesian tenfold
ICV, biWAIC takes into account the model ﬁt of both y and μy. It is interesting, however, that
this does not appear to affect the number of ﬁxed effects that are included in the model: see
Table 2b in the on-line supplementary materials.
Taking into account both of the probability distributions that are associated with the latent
variables (distributions (2) and (3)) better assesses the ﬁt of themodel andprevents the overﬁtting
of the ﬁrst distribution (distribution (2)), keeping the number of included random-effect groups
at a realistic level. nWAIC does not take into account how well the ﬁxed effects wγ can predict
the unknown true HI titres of given pairs of reference and test strains, μy. nWAIC therefore
picks the model which maximizes the ﬁt of distribution (2) regardless of the ﬁt of distribution
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(3), leading to the overﬁtting of distribution (2) and a potentially unrealistically high number
of random-effect groups. It is interesting, however, that we do not see a similar threshold with
Bayesian tenfold ICV, which also takes into account both parts of the latent variable likelihood.
This is a consequence of the different sensitivity versus speciﬁcity trade-offs that are given by
criteria based on WAIC and those based on CV.
7. Results for the A(H1N1) data set
We applied eSABRE to the inﬂuenza A(H1N1) data set that was described in Section 2.1, using
the eight possible combinations of random-effect components. (Each application of the model
took around 2 days on a standard desktop computer.) The biWAIC-score, Section 5.2, was then
calculated for each of the models, with the model with the best biWAIC-score including all
random-effect components. biWAIC was chosen to select the best model on the basis of being
more computationally feasible than tenfold ICV and the results of Table 3 and Figs 4 and 5.
Having selected the model with the best selection of random-effect components according
to biWAIC, we then compared the results in terms of variable selection with those achieved
by Harvey et al. (2016). (Additional plots looking at the goodness of ﬁt of the model selected
can be found in Figs 1 and 2 of the on-line supplementary materials.) Using eSABRE as an
exploratory tool, where we chose a relatively low threshold by taking the top πˆJ and variables
with the highest marginal inclusion probabilities, we selected 11 proven, three plausible and
three implausible residues based on the classiﬁcations that were discussed in Section 2.1. (πˆ is
the maximum a posteriori estimate of the model parameter π. J is the number of variables. We
estimate πˆ ≈ 0:18 and have J = 275. We therefore select 48 variables, 17 of which are residue
variables and 31 are branch variables.)However, for a fair comparisonwith the results ofHarvey
et al. (2016), we also used a more conservative cut-off, selecting only variables with a marginal
inclusion probability of greater than 0.5, which gives the same number of implausible residues
selected. Here we have selected six proven, two plausible and one implausible, compared with
four proven, no plausible and one implausible selected in Harvey et al. (2016). These results,
which are summarized in Table 4, show a clear improvement for eSABRE over the models that
were used in Harvey et al. (2016).
Of the 11 proven residues selected and shown in Fig. 6(a), eSABRE, taking the top πˆJ
variables with the highest marginal inclusion probabilities, has identiﬁed one residue of the
receptor binding site: residue 187. Residue 187 is also part of the Sb antigenic site and we also
Table 4. Summary of H1N1 results†
Method Residue classiﬁcation
Proven Plausible Implausible
Harvey et al. (2016) 4 0 1
eSABRE (top πˆJ variables) 11 3 3
eSABRE (inclusion probability >0:5) 6 2 1
†The table shows the number of proven, plausible and implausible residues
selected by Harvey et al. (2016), the eSABREmethod selecting the top πˆJ vari-
ables and the eSABREmethod selecting any variable with a marginal inclusion
probability of greater than 0.5.
24 V. Davies, W. T. Harvey, R. Reeve and D. Husmeier
(a) (b)
Fig. 6. Three-dimensional structure of the influenza A(H1N1) haemagglutinin protein showing the positions
of proven and plausible antigenic residues identified by using eSABRE: (a) proven residues (black) selected
by eSABRE; (b) labelled plausible residues (black) where the biologically proven sites from Fig.1 are shown in
dark grey; the representation of the surface of haemagglutinin is based on the resolved structure of influenza
A(H1N1) strain A/Puerto Rico/8/34 (Gamblin et al., 2004)
identiﬁed several other nearby residues (184, 189, 190 and 193) belonging to the same antigenic
site. We also identiﬁed proven residues from each of the other known H1 antigenic sites; Ca
(141 and 142), Cb (69 and 74) and Sa (153). Finally we identiﬁed the residue at position 130 to
be important, which is a proven antigenic residue outside these antigenic sites. An amino acid
deletion at this site has been determined to have altered the structure of protein, causing amajor
change in the antigenic properties of the virus which required an update to the vaccine in the
1990s (McDonald et al., 2007).
The three plausible residues that were identiﬁed (66, 146 and 252) can be found between the
Ca and Cb antigenic sites as can be seen in Fig. 6(b). Fig. 6(b) shows the proven antigenic sites
of the A(H1N1) virus (dark grey) and the locations of the plausible residues (black) between
them. Although all the plausible residues could be plausibly antigenic, the most likely to be
signiﬁcant are 66 and 146, which both contact known antigenic sites on the surface of the
protein. Residue 66 occurs directly between and immediately neighbouring two sections of the
Ca and Cb antigenic sites. Both 146 and 252 also occur between sections of the Ca and Cb
antigenic regions; however, residue 146 is in a small indent on the surface and so, although
remaining very plausible, is perhaps less likely than 66. Residue 252 is further away from the
antigenic sites while still remaining in the head region of the virus close to known antigenic sites
and was also picked up by Harvey et al. (2016).
Of the three implausible residues that were identiﬁed (43, 310 and 313), residue 43 has a
reasonable explanationwhy it was selected. Substitutions to the residue at position 43 are known
to have occurred at the same branch of the phylogenetic tree as the important deletion that was
referred to above at position 130, the proven antigenic residue selected by eSABRE described by
McDonald et al. (2007), and in a second branch of the tree associated with a vaccine update. The
by-chance co-occurrence of substitutions at residue 43 and genuine antigenic changes atmultiple
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instances in the evolution of the virus provide an explanation why 43 was identiﬁed both here
and by using other methods (Harvey et al., 2016). The other two implausible residues that were
identiﬁed, 310 and 313, are part of the stalk domain of the H1N1 virus and are unlikely to have
a signiﬁcant antigenic effect. It is, however, noteworthy that residue 313 was identiﬁed at a later,
non-comparable stage of the analysis of Harvey et al. (2016) which involved the identiﬁcation of
speciﬁc amino acid substitutions that correlated with points in the evolution of the virus where
the antigenicity changed.
8. Conclusions and future work
Wehave developed a novel hierarchical Bayesianmodel, called eSABRE, for detecting antigenic
sites in virus evolution, with particular focus on the inﬂuenza virus. Our model is based on a
predecessor, called SABRE, that was developed in the context of studying antigenicity in the
FMDV. However, SABRE turned out to be computationally too inefﬁcient for larger data sets,
as are typically available for the inﬂuenza virus. We have demonstrated that, by building a
new structure of the hierarchical model, we can not only improve the computational efﬁciency
by several orders of magnitude, but we also signiﬁcantly improve the prediction accuracy by
making the model more consistent with the format of the data (see Tables 1 and 2). In addition
to testing eSABRE, we have also looked at the best way of selecting random-effects coefﬁcients.
In Section 5.2 we proposed biWAIC as a new method for selecting random-effect components
in the latent variable models with the structure of eSABRE, where it is not possible to apply
iWAIC. The results of Table 3 and Figs 4 and 5 show how biWAIC properly accounts for
the distribution of the latent variables, resulting in a more realistic number of random-effect
components being included compared with nWAIC and a smaller computational cost than
Bayesian ICV.
Section 7 demonstrates how eSABRE, together with biWAIC, can be effectively applied to
large real life inﬂuenza data sets. In Section 7 we show how the improvement in computational
efﬁciency demonstrated in Table 1, part (b), allows us to make use of the full H1N1 data set
rather than a reduced version as was required for the conjugate SABRE model in Davies et al.
(2017). The results from using the full H1N1 data set and properly accounting for the error in
the data collection process through eSABRE show an improvement in the selection of antigenic
variables in the H1N1 data sets.
Further work involves investigating how different types of amino acid change at the same
residue position on the structure affect antigenic variability. The data currently consist of indi-
cators of amino acid change that are identical regardless of which particular amino acids are
involved. However, given the range of biophysical properties among different amino acids, we
expect the antigenic effect of a change to depend on both the location on the structure and
the particular amino acids that are involved. In Reeve et al. (2016) and Harvey et al. (2016)
variables were used that indicated a particular amino acid change at a given location. This will
signiﬁcantly increase the number of variables that must be selected from and therefore it is likely
that the model will require additional information to prevent spurious results. Latent Gaussian
processes can be used to include the additional information, e.g. Filippone et al. (2013), and
will enable us to account for
(a) differences in the antigenic effect of amino acid substitutions that depend on the amino
acids involved and
(b) similarities between changes of a certain type that occur at the same, or similar, locations
on the protein surface.
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